WALVAX(SZ:300142) Zheng Quan Ri Bao Wang·2025-10-17 10:40Core Viewpoint - Watson Bio (300142) emphasizes its commitment to comply with shareholder information disclosure regulations and aims to build a self-sufficient vaccine industry in China while supplying high-quality products to the global market [1] Group 1: Company Strategy - The company is increasing resource investment across various areas including talent development, project introduction, market marketing, international product registration, clinical trials, international certification, and cooperative production to diversify its international business [1] - Watson Bio is exploring new cooperation models based on its extensive experience to deepen and broaden overseas collaborations, aiming to make innovative vaccines accessible to more people [1] Group 2: Market Positioning - The company aims to enhance its influence in the international market and contribute to global vaccine accessibility [1] - Investors are encouraged to follow the company's announcements for updates on product exports and overseas collaborations [1]